Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
Authors:
- Kentaro MasuhiroKMKentaro Masuhiro
- Motohiro TamiyaMTMotohiro Tamiya
- Kosuke FujimotoKFKosuke Fujimoto
- Shohei KoyamaSKShohei Koyama
- Yujiro NaitoYNYujiro Naito
- Akio OsaAOAkio Osa
- Takashi HiraiTHTakashi Hirai
- Hidekazu SuzukiHSHidekazu Suzuki
- Norio OkamotoNONorio Okamoto
- Takayuki ShiroyamaTSTakayuki Shiroyama
- Kazumi NishinoKNKazumi Nishino
- Yuichi AdachiYAYuichi Adachi
Open Access
- 9 May 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (9)
Abstract
Bronchoalveolar lavage is commonly performed to assess inflammation and identify responsible pathogens in lung diseases. Findings from bronchoalveolar lavage might be used to evaluate the immune profile of the lung tumor microenvironment (TME). To investigate whether bronchoalveolar lavage fluid (BALF) analysis can help identify patients with non–small cell lung cancer (NSCLC) who respond to immune checkpoint inhibitors (ICIs), BALF and blood were prospectively collected before initiating nivolumab. The secreted molecules, microbiome, and cellular profiles based on BALF and blood analysis of 12 patients were compared with regard to therapeutic effect. Compared with ICI nonresponders, responders showed significantly higher CXCL9 levels and a greater diversity of the lung microbiome profile in BALF, along with a greater frequency of the CD56 + subset in blood T cells, whereas no significant difference in PD-L1 expression was found in tumor cells. Antibiotic treatment in a preclinical lung cancer model significantly decreased CXCL9 in the lung TME, resulting in reduced sensitivity to anti–PD-1 antibody, which was reversed by CXCL9 induction in tumor cells. Thus, CXCL9 might be associated with the lung TME microbiome, and the balance of CXCL9 and lung TME microbiome could contribute to nivolumab sensitivity in patients with NSCLC. BALF analysis can help predict the efficacy of ICIs when performed along with currently approved examinations.Keywords
Funding Information
- Japan Society for the Promotion of Science (18H05282,21K07252)
- Japan Agency for Medical Research and Development (15652237,J200705023,J200705710,J200705049,JP18cm016335,JP18cm059042)
- Japan Agency for Medical Research and Development (19cm0106335h0002)
- Ministry of Education, Culture, Sports, Science and Technology (The Center of Innovation program (COISTREAM))
- Ono Pharmaceutical (research grant)
This publication has 64 references indexed in Scilit:
- Improvement of orthotopic lung cancer mouse model via thoracotomy and orotracheal intubation enabling in vivo imaging studiesLaboratory Animals, 2013
- Utility and Applications of Orthotopic Models of Human Non‐Small Cell Lung Cancer (NSCLC) for the Evaluation of Novel and Emerging Cancer TherapeuticsCurrent Protocols in Pharmacology, 2013
- Peripheral Prepositioning and Local CXCL9 Chemokine-Mediated Guidance Orchestrate Rapid Memory CD8+ T Cell Responses in the Lymph NodeImmunity, 2013
- CXCR3 Chemokine Receptor-Ligand Interactions in the Lymph Node Optimize CD4+ T Helper 1 Cell DifferentiationImmunity, 2012
- Topographical Continuity of Bacterial Populations in the Healthy Human Respiratory TractAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancerOncology Reports, 2011
- Incidence et caractéristiques des colonisations des voies respiratoires lors du diagnostic de cancer bronchique : étude rétrospective de 388 casRevue des Maladies Respiratoires, 2011
- Expression mapping using a retroviral vector for CD8+ T cell epitopes: Definition of a Mycobacterium tuberculosis peptide presented by H2-DdJournal of Immunological Methods, 2005
- Cutting Edge: A Murine, IL-12-Independent Pathway of IFN-γ Induction by Gram-Negative Bacteria Based on STAT4 Activation by Type I IFN and IL-18 SignalingThe Journal of Immunology, 2002
- Synergy between Interferon-γ and Tumor Necrosis Factor-α in Transcriptional Activation Is Mediated by Cooperation between Signal Transducer and Activator of Transcription 1 and Nuclear Factor κBJournal of Biological Chemistry, 1997